



Jacqueline Aredo

Fellow in Medicine - Med/Hematology

Bio

PROFESSIONAL EDUCATION

- Master of Science, Stanford University , EPIDM-MS (2021)
- Bachelor of Science, Georgetown University , Neurobiology (2014)
- Doctor of Medicine, Stanford University , MED-MD (2021)
- Board Certification, American Board of Internal Medicine , Internal Medicine (2024)
- Residency, University of California, San Francisco (2024)
- MS, Stanford University School of Medicine (2021)
- MD, Stanford University School of Medicine (2021)

Publications

PUBLICATIONS

- **Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol.** *Future oncology (London, England)*
Aredo, J. V., Peled, N., Arriola, E., Wakelee, H., Ahn, M. J., Kwint, M. H., Taylor, R., van der Gronde, T., Nasirova, F., Chen, M.
2025: 1-7
- **Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Aredo, J. V., Jamali, A., Zhu, J., Heater, N., Wakelee, H. A., Vaklavas, C., Anagnostou, V., Lu, J.
2025; 45 (3): e481114
- **Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.** *JTO clinical and research reports*
Aredo, J. V., Wakelee, H. A., Ramchandran, K. J., Neal, J. W., Diehn, M., Hui, A. B., Salahudeen, A., Kwong, B., Berry, G. J., Guo, H. H., Cunanan, K., Vali, S., Pancirer, et al
2024; 5 (12): 100741
- **Neoadjuvant Osimertinib for the Treatment of Stage I-III A Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Blakely, C. M., Urisman, A., Gubens, M. A., Mulvey, C. K., Allen, G. M., Shiboski, S. C., Rotow, J. K., Chakrabarti, T., Kerr, D. L., Aredo, J. V., Bacaltos, B., Gee, M., Tan, et al
2024: JCO2400071
- **Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Nassar, A. H., Kim, S. Y., Aredo, J. V., Feng, J., Shepherd, F., Xu, C., Kaldas, D., Gray, J. E., Dilling, T. J., Neal, J. W., Wakelee, H. A., Liu, Y., Lin, et al

2024

- **Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.** *Cancer discovery*
Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., Hines, J., Aredo, J. V., Dennis, et al
2023
- **Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study.** *JNCI cancer spectrum*
Aredo, J. V., Choi, E., Ding, V. Y., Tammemagi, M. C., Ten Haaf, K., Luo, S. J., Freedman, N. D., Wilkens, L. R., Le Marchand, L., Wakelee, H. A., Meza, R., Park, S. L., Cheng, et al
2022; 6 (3)
- **Tobacco Smoking and Risk of Second Primary Lung Cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Aredo, J. V., Luo, S. J., Gardner, R. M., Sanyal, N. n., Choi, E. n., Hickey, T. P., Riley, T. L., Huang, W. Y., Kurian, A. W., Leung, A. N., Wilkens, L. R., Robbins, H. A., Riboli, et al
2021
- **Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Aredo, J. V., Mambetsariev, I. n., Hellyer, J. A., Amini, A. n., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., Cabebe, E. C., Naidoo, J. n., Abuali, T. n., Salgia, R. n., Loo, et al
2021
- **Outcomes of atypical EGFR mutations in early-stage EGFR-mutated non-small cell lung cancer (NSCLC).**
Aredo, J. V., Singhal, S., Banwait, M., Guo, E., Piotrowska, Z., Wakelee, H. A., Shrager, J. B., Berry, M. F., Loo Jr, B. W., Diehn, M., Suarez, C. J., Berry, G., Riess, et al
LIPPINCOTT WILLIAMS & WILKINS.2026
- **Corrigendum to "KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status" [Cancer Treatment and Research Communications 47 (2026) 101227].** *Cancer treatment and research communications*
Xu, Z., Aredo, J. V., Su, C. C., Myall, N. J., Roy, M., Ramchandran, K. J., Wakelee, H. A., Neal, J. W.
2026: 101240
- **KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status.** *Cancer treatment and research communications*
Xu, Z., Aredo, J. V., Su, C. C., Myall, N. J., Roy, M., Ramchandran, K. J., Wakelee, H. A., Neal, J. W.
2026; 47: 101227
- **Botulinum toxin for endometriosis-associated chronic pelvic pain: a randomised, double-masked, parallel, phase 2 trial** *ECLINICALMEDICINE*
Karp, B., Tandon, H. K., Sinaii, N., Aredo, J., Phan, V. T., Salmeri, N., Shah, J. P., Merideth, M. A., Stratton, P.
2026; 91
- **Botulinum toxin for endometriosis-associated chronic pelvic pain: a randomised, double-masked, parallel, phase 2 trial.** *EClinicalMedicine*
Karp, B. I., Tandon, H. K., Sinaii, N., Aredo, J. V., Phan, V. T., Salmeri, N., Shah, J. P., Merideth, M. A., Stratton, P.
2026; 91: 103740
- **DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy** *JTO CLINICAL AND RESEARCH REPORTS*
V. Aredo, J., Singhal, S., Berry, G. J., Moradi, F., Wakelee, H. A., Myall, N. J., Ramchandran, K. J., Das, M., Suarez, C. J., Neal, J. W., Riess, J. W.
2025; 6 (12)
- **DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy.** *JTO clinical and research reports*
Aredo, J. V., Singhal, S., Berry, G. J., Moradi, F., Wakelee, H. A., Myall, N. J., Ramchandran, K. J., Das, M., Suarez, C. J., Neal, J. W., Riess, J. W.
2025; 6 (12): 100913
- **Nativity status and non-small cell lung cancer outcomes**
Aredo, J. V., Neal, J. W., Kunder, C. A., Ramchandran, K. J., Myall, N. J., Roy, M., Wakelee, H. A.

AMER ASSOC CANCER RESEARCH.2025: B144

- **Smoking Trends in KRAS-Mutated Non-Small Cell Lung Cancer at a Tertiary Referral Center**
Aredo, J., Neal, J. W., Ramchandran, K. J., Das, M. S., Myall, N. J., Wakelee, H. A.
ELSEVIER SCIENCE INC.2025
- **The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer.** *Molecular cancer*
McDaid, W. J., Wilson, L., Adderley, H., Martinez-Lopez, A., Baker, M. J., Searle, J., Ginn, L., Budden, T., Aldea, M., Marinello, A., Aredo, J. V., Viros, A., Besse, et al
2024; 23 (1): 253
- **Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Nassar, A. H., Jayakrishnan, R., Feng, J., Shepherd, F., Adib, E., Cheung, J. M., Lin, J. J., Liu, Y., Lin, S. H., Parikh, K., Sridhar, A., Shakya, P., Dilling, et al
2024
- **Mindfulness in Facilitating Pelvic Floor Botulinum Toxin Injection in Women with Chronic Pelvic Pain.** *Toxins*
Aredo, J. V., Tandon, H. K., Panahi, S., Phan, V. T., Ameli, R., Karp, B. I., Stratton, P.
2024; 16 (5)
- **Top advances of the year: Perioperative therapy for lung cancer.** *Cancer*
Aredo, J. V., Wakelee, H. A.
2024
- **Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked.** *JAMA network open*
Choi, E., Su, C. C., Wu, J. T., Aredo, J. V., Neal, J. W., Leung, A. N., Backhus, L. M., Lui, N. S., Le Marchand, L., Stram, D. O., Liang, S. Y., Cheng, I., Wakelee, et al
2023; 6 (11): e2343278
- **Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.** *JAMA oncology*
Choi, E., Ding, V. Y., Luo, S. J., Ten Haaf, K., Wu, J. T., Aredo, J. V., Wilkens, L. R., Freedman, N. D., Backhus, L. M., Leung, A. N., Meza, R., Lui, N. S., Haiman, et al
2023
- **Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.** *Cancer*
Choi, E., Luo, S. J., Ding, V. Y., Wu, J. T., Kumar, A. V., Wampfler, J., Tammemägi, M. C., Wilkens, L. R., Aredo, J. V., Backhus, L. M., Neal, J. W., Leung, A. N., Freedman, et al
2023
- **EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)**
Nassar, A., Adib, E., Feng, J., Aredo, J. V., Parikh, K., Harris, J., Manana, A., Ragavan, M., Lin, J., Piotrowska, Z., Fitzgerald, B., Grohe, C., Sankar, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Grant, M. J., Aredo, J. V., Starrett, J. H., Stockhammer, P., van Alderwerelt van Rosenburgh, I. K., Wurtz, A., Piper-Valillo, A. J., Piotrowska, Z., Falcon, C., Yu, H. A., Aggarwal, C., Scholes, D., Patil, et al
2023
- **Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.** *JTO clinical and research reports*
Ji, J., Aredo, J. V., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., Stewart, S., Cobb, R., Wakelee, H. A., Blakely, C. M., Wong, M. L., Gubens, M. A., Madani, et al
2023; 4 (3): 100459
- **Implementation and evaluation of an elective quality improvement curriculum for preclinical students: a prospective controlled study.** *BMC medical education*
Aredo, J. V., Ding, J. B., Lai, C. H., Trimble, R., Bromley-Dulfano, R. A., Popat, R. A., Shieh, L.
2023; 23 (1): 66

- **Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.** *Cancer treatment and research communications*
Aredo, J. V., Wakelee, H. A., Hui, A. B., Padda, S. K., Joshi, N. D., Guo, H. H., Chaudhuri, A., Diehn, M., Loo, B. W., Neal, J. W.
2022; 33: 100659
- **Long term effect of radiotherapy on risk of second primary lung cancer and overall mortality among lung cancer patients**
Choi, E., Lam, V. T., Aredo, J. A., Kumar, A. V., Wampfler, J., Wu, J. T., Christiani, D. C., Cheng, I., Amos, C. I., Hung, R. J., Backhus, L. M., Neal, J. W., Wakelee, et al
AMER ASSOC CANCER RESEARCH.2022
- **High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.** *JTO clinical and research reports*
Piper-Vallillo, A. J., Rotow, J. K., Aredo, J. V., Shaverdashvili, K., Luo, J., Carlisle, J. W., Husain, H., Muzikansky, A., Heist, R. S., Rangachari, D., Ramalingam, S. S., Wakelee, H. A., Yu, et al
2022; 3 (6): 100328
- **Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.**
Grant, M. J., Aredo, J. V., Starrett, J., Wurtz, A., Piotrowska, Z., Piper-Vallillo, A., Yu, H., Falcon, C., Patil, T., Nguyen, C., Aggarwal, C., Scholes, D. G., Li, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.** *Cancer treatment and research communications*
Aredo, J. V., Wakelee, H. A., Neal, J. W., Padda, S. K.
1800; 30: 100497
- **Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Aredo, J. V., Hellyer, J. A., Neal, J. W., Wakelee, H. A.
2021; 16 (12): 1994-1998
- **Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer.** *JCO precision oncology*
Padda, S. K., Aredo, J. V., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., Neal, J. W., Abbasi, T., Wakelee, H. A.
2021; 5: 153-162
- **Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study.** *JNCI cancer spectrum*
Luo, S. J., Choi, E., Aredo, J. V., Wilkens, L. R., Tammemagi, M. C., Le Marchand, L., Cheng, I., Wakelee, H. A., Han, S. S.
2021; 5 (5): pkab076
- **RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BOTULINUM TOXIN FOR ENDOMETRIOSIS-RELATED CHRONIC PELVIC PAIN.**
Stratton, P., Tandon, H. K., Vy Phan, Aredo, J. V., Sinaii, N., Shah, J., Karp, B. I.
ELSEVIER SCIENCE INC.2021: E52
- **A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Aredo, J. V., Wakelee, H. A., Han, S. S.
2021; 16 (8): e59-e60
- **EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.** *Clinical lung cancer*
Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., Neal, J. W.
2021
- **Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer.** *Journal of the National Cancer Institute*
Choi, E., Sanyal, N., Ding, V. Y., Gardner, R. M., Aredo, J. V., Lee, J., Wu, J. T., Hickey, T. P., Barrett, B., Riley, T. L., Wilkens, L. R., Leung, A. N., Le Marchand, et al
2021
- **Randomized, Placebo-Controlled Trial of Botulinum Toxin for Endometriosis-Associated Chronic Pelvic Pain: A Longitudinal Assessment.**
Stratton, P., Tandon, H. K., Phan, V., Aredo, J. V., Sinaii, N., Shah, J. P., Karp, B. I.
SPRINGER HEIDELBERG.2021: 54A-55A

- **The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer**
Choi, E., Luo, S., Aredo, J., Wilkens, L., Leung, A., Le Marchand, L., Cheng, I., Wakelee, H., Han, S.
AMER THORACIC SOC.2021
- **Metabolomic profiling for second primary lung cancer: A pilot case-control study.** *Lung cancer (Amsterdam, Netherlands)*
Aredo, J. V., Purington, N., Su, L., Luo, S. J., Diao, N., Christiani, D. C., Wakelee, H. A., Han, S. S.
2021; 155: 61–67
- **Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer** *JCO PRECISION ONCOLOGY*
Padda, S. K., Aredo, J., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., Neal, J. W., Abbasi, T., Wakelee, H. A.
2021; 5: 153–62
- **Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Hellyer, J. A., Aredo, J. V., Das, M. n., Ramchandran, K. n., Padda, S. K., Neal, J. W., Wakelee, H. A.
2021
- **The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.** *Journal of the National Cancer Institute*
Choi, E., Luo, S. J., Aredo, J. V., Backhus, L. M., Wilkens, L. R., Su, C. C., Neal, J. W., Le Marchand, L., Cheng, I., Wakelee, H. A., Han, S. S.
2021
- **Is smoking a risk factor for second primary lung cancer**
Aredo, J., Luo, S. J., Gardner, R., Hickey, T. P., Riley, T. L., Wilkens, L. R., Le Marchand, L., Amos, C., Hung, R. J., Johansson, M., Cheng, I., Wakelee, H. A., Han, et al
AMER ASSOC CANCER RESEARCH.2020
- **Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.**
Ji, J., Aredo, J., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., Stewart, S. L., Cobb, R., Wakelee, H. A., Blakely, C., Wong, M. L., Gubens, M. A., Chen, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience.**
Piper-Vallillo, A., Rotow, J. K., Aredo, J., Shaverdashvili, K., Luo, J., Carlisle, J. W., Husain, H., Muzikansky, A., Heist, R., Rangachari, D., Ramalingam, S. S., Wakelee, H. A., Yu, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report.** *Clinical lung cancer*
Aredo, J. V., Diehn, M. n., Berry, G. J., Wakelee, H. A.
2020
- **Widespread myofascial dysfunction and sensitisation in women with endometriosis-associated chronic pelvic pain: A cross-sectional study.** *European journal of pain (London, England)*
Phan, V. T., Stratton, P. n., Tandon, H. K., Sinaii, N. n., Aredo, J. V., Karp, B. I., Merideth, M. A., Shah, J. P.
2020
- **Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study** *WORLD NEUROSURGERY*
Huang, Y., Chow, K. K. H., Aredo, J. V., Padda, S. K., Han, S. S., Kakusa, B. W., Gephart, M.
2019; 125: E487–E496
- **EGFR mutation status confers survival benefit in non-small cell lung cancer patients undergoing surgical resection of brain metastases: a retrospective cohort study.** *World neurosurgery*
Huang, Y., Chow, K. K., Aredo, J. V., Padda, S. K., Han, S. S., Kakusa, B. W., Gephart, M. H.
2019
- **Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".** *Lung cancer (Amsterdam, Netherlands)*
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., Wakelee, H. A.
2019

- **Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.** *Lung cancer (Amsterdam, Netherlands)*
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., Wakelee, H. A.
2019; 133: 144–50
- **Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*
Aredo, J. V., Padda, S. K.
2018; 19 (8)
- **Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.** *Current treatment options in oncology*
Aredo, J. V., Padda, S. K.
2018; 19 (8): 43
- **Prognostic impact of KRAS mutation subtype and concurrent genetic mutations in non-small cell lung cancer.**
Aredo, J., Padda, S., Kunder, C., Han, S. S., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2018
- **Beneficial Effects of Dry Needling for Treatment of Chronic Myofascial Pain Persist for 6 Weeks After Treatment Completion.** *PM & R : the journal of injury, function, and rehabilitation*
Gerber, L. H., Sikdar, S., Aredo, J. V., Armstrong, K., Rosenberger, W. F., Shao, H., Shah, J. P.
2017; 9 (2): 105-112
- **Relating Chronic Pelvic Pain and Endometriosis to Signs of Sensitization and Myofascial Pain and Dysfunction.** *Seminars in reproductive medicine*
Aredo, J. V., Heyrana, K. J., Karp, B. I., Shah, J. P., Stratton, P.
2017; 35 (1): 88-97
- **Myofascial Trigger Points Then and Now: A Historical and Scientific Perspective.** *PM & R : the journal of injury, function, and rehabilitation*
Shah, J. P., Thaker, N., Heimur, J., Aredo, J. V., Sikdar, S., Gerber, L.
2015; 7 (7): 746-761